research use only
Cat.No.S1934
| Related Targets | Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV |
|---|---|
| Other Antibiotics for Mammalian Cell Culture Inhibitors | Tylosin tartrate |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 926.09 | Formula | C47H75NO17 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1400-61-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Fungicidin | Smiles | CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1OC3CC(C(C(O3)C)O)O)C)C)O)O)O)O)O)O)O)C(=O)O)OC4C(C(C(C(O4)C)O)N)O | ||
| In vitro |
Nystatin results in a significant reduction in buccal epithelial cell adhesion of all six Candida species. This compound is an antibiotic that increases the permeability of plasma membranes to small monovalent ions, including chloridion. It increases apical chloridion permeability to the point where transepithelial chloridion transport is limited by transport across the basolateral membrane of tracheal epithelial cells, which reflects primarily the activity of the cotransporter. This chemical (400 units/ml) increases the basal level of transepithelial 36Cl flux approximately 1.5-fold and eliminates UTP stimulation of this flux. This treatment also abolishes UTP stimulation of saturable, basolateral [3H]bumetanide binding, a measure of functioning Na-K-Cl cotransporters in these cells; isoproterenol stimulation of binding is only mildly inhibited by nystatin treatment. It significantly enhances endostatin uptake by endothelial cells through switching endostatin internalization predominantly to the clathrin-mediated pathway. This compound-enhanced internalization of endostatin also increases its inhibitory effects on endothelial cell tube formation and migration. |
|---|---|
| In vivo |
Nystatin combined with endostatin selectively enhances endostatin uptake and biodistribution in tumor blood vessels and tumor tissues but not in normal tissues of tumor-bearing mice, ultimately resulting in elevated antiangiogenic and antitumor efficacies of endostatin in vivo. Liposomal this compound, at doses as low as 2 mg/kg of body weight/day, protects neutropenic mice against Aspergillus-induced death in a statistically significant manner at the 50-day time point compared to either the no-treatment, the saline, or the empty-liposome group. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01531192 | Completed | Very Low Birth Weight Infants |
Zekai Tahir Burak Women''s Health Research and Education Hospital |
June 2012 | Phase 4 |
| NCT01411748 | Unknown status | Anticandidal Property of Saccharomyces Boulardii on Very Low Birth Weight Infants |
Zekai Tahir Burak Women''s Health Research and Education Hospital |
July 2011 | Phase 4 |
| NCT01427738 | Completed | HIV-1 Infection |
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections|National Institute of Allergy and Infectious Diseases (NIAID) |
June 2011 | Phase 3 |
| NCT03390374 | Completed | Fungal Infections Systemic |
Dr Cipto Mangunkusumo General Hospital |
October 2010 | Phase 4 |
| NCT02642900 | Completed | Photochemotherapy Reaction |
University of Sao Paulo |
July 2009 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.